OptimizeRxOPRX
OPRX
0
Funds holding %
of 7,398 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
63% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 19
12% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 17
2% more funds holding
Funds holding: 85 [Q3] → 87 (+2) [Q4]
5.86% less ownership
Funds ownership: 67.58% [Q3] → 61.72% (-5.86%) [Q4]
42% less capital invested
Capital invested by funds: $95.6M [Q3] → $55.3M (-$40.3M) [Q4]
87% less call options, than puts
Call options by funds: $75K | Put options by funds: $569K
100% less funds holding in top 10
Funds holding in top 10: 1 [Q3] → 0 (-1) [Q4]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$6
25%
downside
Avg. target
$7
13%
downside
High target
$8
1%
downside
2 analyst ratings
1 positive
50%
1 neutral
50%
0 negative
0%
JMP Securities Constantine Davides 30% 1-year accuracy 10 / 33 met price target | 1%downside $8 | Market Outperform Reiterated | 6 Feb 2025 |
RBC Capital Sean Dodge 31% 1-year accuracy 11 / 35 met price target | 25%downside $6 | Sector Perform Downgraded | 8 Jan 2025 |
Financial journalist opinion
Based on 6 articles about OPRX published over the past 30 days
Positive
Benzinga
2 weeks ago
OptimizeRx Clocks Double-Digit Revenue Growth In Q4, Forecasts Sales Of At Least $100 Million
OPTIMIZERx Corp. OPRX, a health care technology firm, reported on Wednesday fourth-quarter sales of $32.32 million, up 14% year-over-year, beating the consensus of $30.36 million.

Neutral
Seeking Alpha
2 weeks ago
OptimizeRx Corporation (OPRX) Q4 2024 Earnings Call Transcript
OptimizeRx Corporation (NASDAQ:OPRX ) Q4 2024 Results Conference Call March 12, 2025 8:30 AM ET Company Participants Steve Silvestro - President Edward Stelmakh - Chief Financial Officer and Chief Operational Officer Andrew D'Silva - Senior Vice President of Corporate Finance Conference Call Participants Jared Haase - William Blair Anderson Schock - B. Riley Constantine Davides - Citizens JMP Richard Baldry - ROTH Capital David Grossman - Stifel Financial Eric Martinuzzi - Lake Street Jeff Garro - Stephens, Inc Operator Good morning, everyone, and thank you for joining OptimizeRx's Fourth Quarter and Full Year Fiscal 2024 Earnings Conference Call.

Positive
Zacks Investment Research
2 weeks ago
OptimizeRx Corp. (OPRX) Q4 Earnings and Revenues Beat Estimates
OptimizeRx Corp. (OPRX) came out with quarterly earnings of $0.30 per share, beating the Zacks Consensus Estimate of $0.25 per share. This compares to earnings of $0.26 per share a year ago.

Neutral
GlobeNewsWire
2 weeks ago
OptimizeRx Reports Strong Fourth Quarter and Full Year 2024 Financial Results
WALTHAM, Mass., March 12, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced results for the fourth quarter and full year ended December 31, 2024.

Neutral
GlobeNewsWire
3 weeks ago
OptimizeRx Corporation Confirms Receipt of Notice of Director Nominations
WALTHAM, Mass., March 11, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today confirmed that it has received a purported notice of nominations from a stockholder, Whetstone Capital Advisors, LLC, regarding its intention to nominate two candidates for election to the OptimizeRx Board of Directors at the Company's 2025 Annual Meeting of Stockholders.

Neutral
GlobeNewsWire
3 weeks ago
OptimizeRx Corporation Appoints Stephen Silvestro as Chief Executive Officer
Silvestro has a demonstrated record of accelerating revenue growth, expanding brand relevance, and building a market-leading team Silvestro has a demonstrated record of accelerating revenue growth, expanding brand relevance, and building a market-leading team

Neutral
GlobeNewsWire
1 month ago
OptimizeRx Sets Fourth Quarter and Full Year 2024 Financial Results Conference Call for March 12, 2025, at 8:30 a.m. ET
WALTHAM, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professional (HCPs) and patients, will hold a conference call on Wednesday, March 12, 2025, at 8:30 a.m. Eastern Time to discuss full year fiscal 2024 financial results and the fourth quarter period ended December 31, 2024. The financial results will be issued in a press release prior to the call.

Neutral
GlobeNewsWire
3 months ago
OptimizeRx Announces Departure of CEO William Febbo and Appointment of Stephen Silvestro as Interim CEO
WALTHAM, Mass., Dec. 23, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced that William J. Febbo, Chief Executive Officer (CEO) and Board Member, will be departing the Company, effective as of December 31, 2024, to pursue other opportunities. Mr. Febbo will provide the Company with advisory services through March 31, 2025. The Company's Board of Directors has retained a search firm to assist in this transition.

Neutral
GlobeNewsWire
4 months ago
OptimizeRx to Participate in Upcoming Investor Conferences
WALTHAM, Mass., Nov. 18, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp . (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professional (HCPs) and patients, today announced that management will participate in the following upcoming investor conferences:

Neutral
Seeking Alpha
4 months ago
OptimizeRx Corporation (OPRX) Q3 2024 Earnings Call Transcript
OptimizeRx Corporation (NASDAQ:OPRX ) Q3 2024 Results Earnings Conference Call November 13, 2024 4:30 PM ET Company Participants William Febbo - Chief Executive Officer Edward Stelmakh - Chief Financial Officer and Chief Operational Officer Steve Silvestro - President Conference Call Participants Ryan Daniels - William Blair & Company, LLC Sean Dodge - RBC Capital Markets Kyle Bauser - B. Riley Securities David Grossman - Stifel Financial Constantine Davides - Citizens JMP Stephanie Davis - Barclays Operator Good afternoon, everyone, and thank you for joining OptimizeRx's Third Quarter Fiscal 2024 Earnings Call.

Charts implemented using Lightweight Charts™